Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 6/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ATP4A | P20648 | 2/20 | 0.32 |
| ▸ | ATP4B | P51164 | 2/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274376 | 0.79 | TRPA1 (0.33) | TRPA1ALDH1A1TSHR | |
| SCHEMBL2727083 | 0.77 | IDO1 (0.50) | IDO1ALDH1A1TSHRHPGD | |
| SCHEMBL2728342 | 0.75 | IDO1 (0.51) | IDO1FYNALDH1A1 | |
| SCHEMBL6953152 | 0.74 | METAP2 (0.50) | ALDH1A1TSHRGLAHPGD | |
| SCHEMBL1259618 | 0.73 | TRPA1 (0.52) | CYP4F2CYP4A11PRMT6TRPA1ALDH1A1 | |
| SCHEMBL30987236 | 0.73 | TRPA1 (0.52) | CYP4F2CYP4A11PRMT6TRPA1ALDH1A1 | |
| SCHEMBL4559345 | 0.72 | KMT2A (0.42) | IDO1ALDH1A1GLAHPGD | |
| SCHEMBL9454514 | 0.71 | CYP4F2 (0.44) | CYP4F2CYP4A11IDO1PRMT6TRPA1 | |
| SCHEMBL6164219 | 0.70 | CDK8 (0.44) | ALDH1A1CDK8 | |
| SCHEMBL5727823 | 0.70 | DYRK1A (0.49) | CYP4F2CYP4A11FYNALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| EP-2038283-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7402595-B2 | Enzyme inhibitors with isoquinolinone structures | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1910367-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | disclosed |
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1392686-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-03 | — | — | EP | disclosed |
| US-6635647-B2 | Such as (4-(3,4-difluoro-phenyl)-piperazin-1-yl)-((4,4,8)-2-(3-(6-methoxy-pyridin-3 -yl)-2-methyl-propyl)-decahydro-isoquinolin-4-yl)-methanone; schizophrenia, depression, anxiety, bipolar disorders | NOVARTIS AG (CH) | 2003-10-21 | — | — | US | disclosed |
| EP-1343780-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2003-09-17 | — | — | EP | disclosed |
| US-20030120072-A1 | Such as (4-(3,4-Difluoro-phenyl)-piperazin-1-yl)-((4S ,4aS,8aR)-2-((S)-3-(6-methoxy-pyridin-3-yl)-2-methyl-propyl)-decahydro -isoquinolin-4yl)-methanone for treatment of schizophrenia, depression, anxiety and bipolar disorders | NOVARTIS AG (CH) | 2003-06-26 | — | — | US | disclosed |
| EP-1268466-A1 | DECAHYDRO-ISOQUINOLINES | Novartis AG (CH) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002096907-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002050061-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-27 | — | — | WO | disclosed |
| WO-2001070731-A1 | DECAHYDRO-ISOQUINOLINES | NOVARTIS AG (CH) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | NRDC, NUCB2, ASNS | CYP4F2 2595/4885CYP4A11 4426/4885IDO1 1159/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | CYP4F2 2810/4885CYP4A11 1793/4885IDO1 374/4885 |
| US-20030120072-A1 | Such as (4-(3,4-Difluoro-phenyl)-piperazin-1-yl)-((4S ,4aS,8aR)-2-((S)-3-(6-methoxy-pyridin-3-yl)-2-methyl-propyl)-decahydro -isoquinolin-4yl)-methanone for treatment of schizophrenia, depression, anxiety and bipolar disorders | MC2R, SSTR1, NPY2R | CYP4F2 1120/4885CYP4A11 649/4885IDO1 1506/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | CYP4F2 2810/4885CYP4A11 1793/4885IDO1 374/4885 |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CYP4F2 2810/4885CYP4A11 1793/4885IDO1 374/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CYP4F2 2810/4885CYP4A11 1793/4885IDO1 374/4885 |
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | MYD88, THPO, PIGO | CYP4F2 2350/4885CYP4A11 3727/4885IDO1 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.